Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

NCT04425655 PHASE2 TERMINATED

This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.

Details

Lead sponsor	University of California, San Diego
Phase	PHASE2
Status	TERMINATED
Enrolment	2
Start date	Wed Aug 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acute Myeloid Leukemia, Adult
• AML
• AML, Adult

Interventions

• Fludarabine
• Vyxeos

Countries

United States